Eluxan

Eluxan is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

The recommended dose is 75 mg tablet taken orally twice daily with food. Patients who develop severe constipation for more than 4 days have to discontinue the drug. If a dose is missed, patient should take the next dose at the regular time and avoid taking two doses at a time.

Pediatric Use

: Safety and effectiveness in pediatric patients have not been established.

Hepatic Impairment

: It is contraindicated in patients with severe hepatic impairment.

Eluxadoline is a mu-opioid receptor agonist, kappa opioid receptor agonist & delta opioid receptor antagonist. Eluxadoline works directly in intestine to reduce peristalsis, also makes the nerves in intestine less sensitive to stimulation.

Most common adverse reactions are constipation, nausea and abdominal pain.

Known or suspected biliary duct obstruction, sphincter of oddi disease or dysfunction & pancreatitis.

Sphincter of Oddi spasm and Pancreatitis.

• Patients who should be monitored closely-
• without a gallbladder
• with new or worsening abdominal pain
• with nausea and vomiting
• with acute biliary pain
• with liver or pancreatic enzyme elevation

Pregnancy: Not established.

Lactation: Not established.

Oral Contraceptive, Cyclosporine, Probenecid, Rosuvastatin.

Store in a cool & dry place, protect from light. Keep out of the reach of children.